Role of endothelial nitric oxide synthase VNTR (intron 4 a/b) polymorphism on the progression of renal disease in autosomal dominant polycystic kidney disease

Ramprasad Elumalai¹, Soundararajan Periasamy²*, Gnanasambandan Ramanathan² Bhaskar VKS Lakkakula²³

¹Department of Nephrology, Sri Ramachandra Medical College and Hospital, Sri Ramachandra University, Chennai, India
²Department of Biomedical Sciences, Sri Ramachandra University, Chennai, India
³Sickle Cell Institute Chhattisgarh, Raipur, India

Introduction:
Autosomal dominant polycystic kidney disease (ADPKD) is an inherited disorder, and it is mainly associated with renal cyst formation. Several studies have also shown that these mutations regulate the physiology of epithelial tissues and determine renal cyst formation and growth in polycystic kidney disease (PKD). Nitric oxide (NO) is also considered to be an important factor involved in the deterioration of renal function.

Objectives:
The aim of the current study is to determine the frequency of NOS3 27-bp VNTR in ADPKD patients and to investigate the role of NOS3 27-bp VNTR genotypes in the modification of progression of renal disease in ADPKD.

Patients and Methods:
The hypothesis was investigated by studying the South Indian population of 53 ADPKD patients and 94 unrelated healthy controls. The genotyping was performed by polymerase chain reaction and electrophoresis. Genotypes were compared between ADPKD and controls using the χ²-test. Univariate and multivariate logistic regression analyses were performed to assess the effect of genotypes and hypertension on the progression of chronic kidney disease (CKD). A stratified analysis was also performed to assess the evidence of the modification of hypertension-CKD relationship among VNTR genotypes.

Results:
The NOS3 4a allele frequencies were 21.3% and 13.2% respectively for controls and ADPKD groups. The NOS3 VNTR genotypes and alleles were not associated with ADPKD. The univariate analysis showed that age, hypertension and NOS3 VNTR influenced the advancement of CKD.

Conclusion:
The present study confirms the significant association between the 27-bp VNTR and CKD advancement among the ADPKD patients in the South Indian population.

Implication for health policy/practice/research/medical education:
In the present study, nitric oxide synthase (NOS 3) gene 27-bp VNTR polymorphism was investigated in autosomal dominant polycystic kidney disease (ADPKD) and healthy subjects. This study demonstrated that the distribution of NOS3 VNTR genotypes in ADPKD did not differ from those in controls. But the influence of NOS3 VNTR on the progression of chronic kidney disease (CKD) in ADPKD was observed. NOS3 VNTR 4a allele might be a valuable indicator in the prediction of progress of CKD in south Indian populations.

Please cite this paper as: Elumalai R, Periasamy S, Ramanathan G, Lakkakula BV. Role of endothelial nitric oxide synthase VNTR (intron 4 a/b) polymorphism on the progression of renal disease in autosomal dominant polycystic kidney disease. J Renal Inj Prev 2014; 3(3): 69-73. DOI: 10.12861/jrip.2014.21

Introduction
Autosomal dominant polycystic kidney disease (ADPKD) is an inherited disorder of worldwide origin, caused by mutations of polycystic kidney disease (PKD) genes, PKD1 or PKD2 (1). It is predominantly associated with renal cyst formation. Several studies have also shown that these mutations regulate the physiology of epithelial tissues and determine the renal cyst formation and growth in PKD
Elumalai R et al.

Several lines of evidence suggest that the endothelial dysfunction, secondary to an impaired release of nitric oxide (NO), exists in ADPKD (1,2). NO is the molecular counterpart of the endothelium-derived relaxing factor and a key signaling molecule that controls blood pressure and nerve impulses (4-6). NO is synthesized by the endothelial NO synthase (eNOS) through the conversion of L-arginine to L-citrulline, using molecular oxygen. The gene coding for eNOS (NOS3) is located on 7q36 (7). ADPKD is associated with altered endothelial-dependent vasodilation and decreased vascular production of NO. This has led to the hypothesis that it might be a modifier gene in ADPKD (8-10). Several single nucleotide polymorphisms (SNPs) have also been described in the NOS3 gene and some of them have been associated with altered eNOS function, leading to impaired NO synthesis. A missense variant in exon 7 (Glu298Asp) and 27-base pair (bp) variable number of tandem repeat (VNTR) in the intron-4 of NOS3 gene are known to alter eNOS expression (11,12). The relationship between NOS3 gene polymorphisms and some diseases have already been reported (13-16). Further, reports have also shown that eNOS (NOS3) 27-bp VNTR polymorphism might have a modifier effect on the ADPKD progression (11). Nevertheless, there is no data available with reference to the NOS3 gene polymorphisms and their association with ADPKD or its progression in the Indian population.

Objectives
The objectives of the current study were to determine the frequency of NOS3 27-bp VNTR in ADPKD patients and to further investigate the modification of renal disease progression in ADPKD by the NOS3 27-bp VNTR genotypes.

Patients and Methods
Study population
The study population comprised of a total of 147 individuals (53 ADPKD and 94 controls), who were selected from the Department of Nephrology, Sri Ramachandra University, Chennai, India.

Laboratory study
Hematological, serum biochemical and electrolyte indices were measured for all the study subjects. Estimated glomerular filtration rate (eGFR) was assessed based on Modification of Diet in Renal Disease (MDRD) formula (17). The total number of cysts in the ADPKD patients was detected by using ultrasound imaging. Only those ADPKD patients, who fulfilled the standard diagnostic criteria, were included in the study (18). Further, the stage of chronic kidney disease (CKD) of the study subjects was determined using eGFR and all the ADPKD patients were then divided into two groups; early (CKD stages 1-3) and advanced stages (CKD stages 4 and 5). Individuals without diabetes, hypertension and kidney related diseases were considered as controls. Three mL of blood samples were collected from all the participants and DNA was extracted from whole blood by the Phenol chloroform extraction and ethanol precipitation techniques (19). Genotyping for NOS3 27-bp VNTR polymorphism was performed by PCR-electrophoresis methods (20). The amplicons were examined by agarose gel electrophoresis. The PCR amplicon's size of 393 bps corresponded to 4a/a homozygotes, 420 bps to 4b/b homozygotes and 420 bps to 4a/b hetrozygotes.

Ethical issues
The study was approved by the Institutional Ethics Committee of the Sri Ramachandra University, Chennai, India. A written informed consent was obtained from all the study participants.

Statistical analysis
Allele frequencies were determined by direct counting of alleles at each locus. The genotype distribution was evaluated for Hardy–Weinberg’s equilibrium (HWE). The association between NOS3 27-bp VNTR polymorphisms and ADPKD was analyzed using χ²-test. Odds ratios and 95% confidence intervals (CIs) were calculated. Univariate and multivariate logistic regression analyses were performed to assess the effect of genotypes and hypertension on CKD progression in ADPKD. Mantel-Haenszel stratified analysis was also performed to assess the modifying effects of NOS3 27-bp VNTR. All statistical analyses were performed with SPSS statistical software version 16.0 (SPSS Inc, Chicago, Illinois) for Microsoft Windows.

Results
Participants of the study comprised of 94 controls and 53 patients with ADPKD. The mean ages of the study participants were 52.1±12.2 years for the control group and 49.20±10.1 years for ADPKD cases. The NOS3 27-bp VNTR genotypes are following the HWE in control group as well as in ADPKD group (Table 1). The NOS3 VNTR mutation was found in 36 (38.3%) controls and 12 (22.6%) ADPKD cases. The NOS3 4a allele frequencies were 21.3% and 13.2% respectively for controls and ADPKD cases. The NOS3 genotypes were not significantly associated with ADPKD (p= 0.136). The NOS3 VNTR did not show a significant association with ADPKD at allele level (4b vs. 4a: OR= 0.563, 95% CI = 0.290–0.109, p= 0.086) (Table 1). Among ADPKD, 37 (69.8%) cases showed advanced CKD stages with mean age of 51.6±10.7 yrs and 16 cases (30.2%) ADPKD cases. The NOS3 4a allele frequencies were 21.3% and 13.2% respectively for controls and ADPKD cases. The NOS3 genotypes were not significantly associated with ADPKD (p= 0.136). The NOS3 VNTR did not show a significant association with ADPKD at allele level (4b vs. 4a: OR= 0.563, 95% CI = 0.290–0.109, p= 0.086) (Table 1). Among ADPKD, 37 (69.8%) cases showed advanced CKD stages with mean age of 51.6±10.7 yrs and 16 cases (30.2%) showed early CKD stages with 39.8 ± 11.7 yrs of age. The NOS3 VNTR was found to be associated with mutant allele and was observed only in the advanced CKD stage group (Table 2). The univariate analysis revealed that the age and hypertension had contributed to the significant advancement of CKD, while the gender and family history of diabetes had no effect on CKD advancement (Table 2). After controlling for the other variables in multivariate analysis, only NOS3 VNTR mutant genotypes and age were found to significantly increase the risk of CKD.
Discussion
In view of the strong association of ADPKD with hypertension, the eNOS enzyme responsible for NO production and variations in its gene expression could be linked to hypertension. In this context, NOS3 gene has long been thought of as a candidate gene for ADPKD. In this study, after investigating 94 controls and 53 ADPKD subjects, no significant association was observed between the genotypes and alleles of NOS3 27-bp and ADPKD. The univariate analysis revealed that the NOS3 VNTR, age and hypertension contributed to the advancement of CKD. After controlling other variables in multivariate analysis, only VNTR genotypes and age were found to increase the risk of CKD advancement in ADPKD. Stratified analysis further showed that the NOS3 VNTR was an effect modifier of the relationship between hypertension and CKD advancement among the ADPKD patients. The results were also consistent with the existing reports in this regard. The first study linking this VNTR and hypertension was published by Miyamoto and co-workers (21). Though these findings were not substantiated in the Australian population (22), a positive

Table 1. Results of association tests between NOS3 27-bp VNTR polymorphism and ADPKD patients in different models

| Genotype | Controls n (%) | ADPKD n (%) | OR (95% CI) | P value |
|----------|----------------|--------------|-------------|---------|
| 4bb      | 58 (61.7)      | 41 (77.3)    | Reference   |         |
| 4ab      | 32 (34)        | 10 (18.9)    | 0.442 (0.195-0.999) | 0.136* |
| 4aa      | 4 (4.3)        | 2 (3.8)      | 0.707 (0.124-4.045) |         |
| 4ab+4aa  | 36 (38.3)      | 12 (22.7)    | 0.472 (0.219-1.014) | 0.052   |
| 4b       | 148 (78.7)     | 92 (86.8)    | Reference   |         |
| 4a       | 40 (21.3)      | 14 (13.2)    | 0.563 (0.290-0.109) | 0.086   |
| HWP      | 0.875          | 0.197        |             |         |

4b: NOS3 VNTR wild type allele; 4a: NOS3 VNTR mutant allele; HWP: Hardy-Weinberg equilibrium p value. *degrees of freedom (d.f)=2

Table 2. Characteristics of ADPKD cases and their association with chronic kidney disease stage.

| Gene     | Genotype | Early stage (%) | Advanced stage (%) | OR (95% CI) | P value (χ²) | OR (95% CI) | Wald’s test p value |
|----------|----------|-----------------|-------------------|-------------|--------------|-------------|-------------------|
| NOS3 VNTR| 4bb      | 16 (100)        | 25 (67.6)         | 1           |              |             | 1                 |
|          | 4ab      | 0 (0)           | 10 (27.0)         | -           | 0.035        | -           | -                 |
|          | 4aa      | 0 (0)           | 2 (5.4)           | -           |              | -           | -                 |
| ≤40      |          | 10 (62.5)       | 7 (18.9)          | 1           |              | 1           | 1                 |
| Age      | (40-60)  | 5 (31.3)        | 22 (59.5)         | 6.29 (1.60,24.73) | 0.007        | 6.59 (1.19,36.60) | 0.031 |
|          | >60      | 1 (6.3)         | 8 (21.6)          | 11.43 (1.16,113.16) | -           | -           | -                 |
| Sex      | F        | 7 (26.9)        | 17 (45.9)         | 1           |              |             | 1                 |
|          | M        | 19 (73.1)       | 20 (54.1)         | 1.09 (0.34,3.56) | 0.562        | 1.55 (0.28,8.67) | 0.619 |
| HT       | No       | 6 (37.5)        | 1 (2.7)           | 1           |              |             | 1                 |
|          | Yes      | 10 (62.5)       | 36 (97.3)         | 21.6 (2.32,200.86) | 0.002        | 21.6 (2.32,200.86) | 0.001 |
| FH-DM    | No       | 2 (12.5)        | 10 (27.0)         | 1           |              |             | 1                 |
|          | Yes      | 14 (87.5)       | 27 (73.0)         | 3.86 (0.074,2.01) | 0.215        | 0.547 (0.075,3.99) | 0.552 |

FH-DM: family history of diabetes mellitus

Table 3. Association between CKD stages and hypertension stratified by NOS3 VNTR genotypes.

| Gene     | Genotype | OR(95% CI) for HT | Homogeneity test | P-value |
|----------|----------|------------------|-----------------|---------|
| NOS3 VNTR| 4bb      | 14.4 (1.53,135.52) |                 |         |
|          | 4ab      | -                | NA              |         |
|          | 4aa      | -                | NA              |         |
| M-H combined|        | 14.4 (1.53,135.52) |                 |         |
association was observed between the plasma nitrite or nitrate levels and blood pressure in normotensive African Americans (23). Further, the a/a genotype of the NOS3 VNTR was shown to significantly increase the risk of developing hypertension in Indian men (24). Following the conflicting results generated from these association studies, Intron 4 VNTR and haplotype analysis of several other SNPs of NOS3 showed significant association with daytime systolic blood pressure (25). In the present study 4a allele was significantly associated with CKD advancement in ADPKD. Higher incidence of 4a allele was observed among Czech patients with end-stage renal disease (ESRD) caused by ADPKD (26). On the contrary, NOS3 VNTR polymorphism showed no effect on the age at ESRD in unrelated ADPKD patients from Belgium and the north of France (11). Several studies have demonstrated that a decrease of NO synthesis and release may be important in the progression of renal disease (27), and a significant endothelial dysfunction has also been documented in ADPKD patients (28). Direct analysis of NOS3 gene polymorphisms in ADPKD patients have also revealed inconclusive results from many populations. Although no direct association between NOS3 VNTR and ADPKD has been observed, patients who carried 4a allele showed faster ESRD progression in the group of ADPKD (29). Higher frequency of the NOS3 4a allele carriers among CKD children suggests that the NOS3 VNTR may be associated with an increased risk of chronic renal failure (30).

Conclusion
In conclusion, we identified the significant association between NOS3 27-bp VNTR and CKD progression in ADPKD. However, more focused research in this regard is required to further validate our findings.

Acknowledgements
The authors would like to thank Sri Ramachandra University for providing necessary facilities and the subjects.

Authors’ contributions
RE, SP and BLVKS conceived the study and contributed reagents and tools. RE, GR and BLVKS performed the experiments. RE and BLVKS analyzed the data and drafted the final manuscript; all authors read, revised, and approved the final manuscript.

Conflict of interests
The authors declared no competing interests.

Ethical considerations
Ethical issues (including plagiarism, data fabrication, double publication) have been completely observed by the author.

Funding/Support
No funding from any source.

References
1. Harris PC. 2008 Homer W Smith Award: insights into the pathogenesis of polycystic kidney disease from gene discovery. J Am Soc Nephrol 2009;20(6):1188-98.
2. Gascue C, Katsanis N, Badano JL. Cystic diseases of the kidney: ciliary dysfunction and cystogenic mechanisms. Pediatr Nephrol 2011;26(8):1181-95.
3. Devuyst O, Persu A, Vo-Cong MT. Autosomal dominant polycystic kidney disease: modifier genes and endothelial dysfunction. Nephrol Dial Transplant 2003;18(11):2211-5.
4. Moncada S, Radomski MW, Palmer RM. Endothelium-derived relaxing factor. Identification as nitric oxide and role in the control of vascular tone and platelet function. Biochem Pharmacol 1988;37(13):2495-501.
5. Rutkevich SA, Polenov SA, Chumak AG, Kulchitsky VA. Impulse flow in sympathetic efferents of the abdominal aortic nerve after intrathecal administration of the substrate and inhibitor of nitric oxide synthase. Bull Exp Biol Med 2009;147(3):281-4.
6. Mize RR, Lo F. Nitric oxide, impulse activity, and neurotrophins in visual system development(1). Brain Res 2000;886(1-2):15-32.
7. Marsden PA, Heng HH, Scherer SW, Stewart RJ, Hall AV, Shi XM, et al. Structure and chromosomal localization of the human constitutive endothelial nitric oxide synthase gene. J Biol Chem 1993;268(23):17478-88.
8. Devuyst O. Variable renal disease progression in autosomal dominant polycystic kidney disease: a role for nitric oxide? J Nephrol 2003;16(3):449-52.
9. Wang D, Iversen J, Wilcox CS, Strandgaard S. Endothelial dysfunction and reduced nitric oxide in resistance arteries in autosomal-dominant polycystic kidney disease. Kidney Int 2003;64(4):1381-8.
10. Wang D, Braendstrup O, Larsen S, Horn T, Strandgaard S. The expression and activity of renal nitric oxide synthase and circulating nitric oxide in polycystic kidney disease rats. APMIS 2004;112(6):358-68.
11. Persu A, Stoenoiu MS, Messiah R, Davila S, Robino C, El-Khattabi O, et al. Modifier effect of ENOS in autosomal dominant polycystic kidney disease. Hum Mol Genet 2002;11(3):229-41.
12. Wang XL, Sim AS, Wang MX, Murrell GA, Trudinger B, Wang J. Genotype dependent and cigarette specific effects on endothelial nitric oxide synthase gene expression and enzyme activity. FEBS Lett 2000;471(1):45-50.
13. Ramirez-Patino R, Figuera LE, Puebla-Perez AM, Delgado-Saucedo JI, Legazpi-Macias MM, Mariad-Schmidt RP, et al. Intron 4 VNTR (4a/b) Polymorphism of the Endothelial Nitric Oxide Synthase Gene Is Associated with Breast Cancer in Mexican Women. J Korean Med Sci 2013;28(11):1587-94.
14. Jemaa R, Kallel A, Sediri Y, Abdessalem S, Mourali MS, Feki M, et al. Association between endothelial nitric oxide gene intron 4a/b VNTR polymorphism and plasma homocysteine concentrations in Tunisian
male patients with myocardial infarction. *Nutr Res* 2012;32(5):342-6.

15. Mehrab-Mohseni M, Tabatabaei-Malazy O, Hasani-Ranjbar S, Amir P, Kouroshnia A, Bazzaz JT, *et al.* Endothelial nitric oxide synthase VNTR (intron 4 a/b) polymorphism association with type 2 diabetes and its chronic complications. *Diabetes Res Clin Pract* 2011;91(3):348-52.

16. Yeh CC, Santella RM, Hsieh LL, Sung FC, Tang R. An intron 4 VNTR polymorphism of the endothelial nitric oxide synthase gene is associated with early-onset colorectal cancer. *Int J Cancer* 2009;124(7):1565-71.

17. NKF. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. *Am J Kidney Dis* 2002;39(2 Suppl 1):S1-266.

18. Ravine D, Gibson RN, Walker RG, Sheffield LJ, Kincaid-Smith P, Danks DM. Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1. *Lancet* 1994;343(8901):824-7.

19. Sambrook J, Russell DW. *Molecular cloning : a laboratory manual*. 3rd ed. N.Y.: Cold Spring Harbor Laboratory Press; 2001.

20. Yoon Y, Song J, Hong SH, Kim JQ. Plasma nitric oxide concentrations and nitric oxide synthase gene polymorphisms in coronary artery disease. *Clin Chem* 2000;46(10):1626-30.

21. Miyaomoto Y, Saito Y, Kajiyama N, Yoshimura M, Shimasaki Y, Nakayama M, *et al.* Endothelial nitric oxide synthase gene is positively associated with essential hypertension. *Hypertension* 1998;32(1):3-8.

22. Benjafield AV, Morris BJ. Association analyses of endothelial nitric oxide synthase gene polymorphisms in essential hypertension. *Am J Hypertens* 2000;13(9):994-8.

23. Li R, Lyn D, Lapu-Bula R, Oduwole A, Igbo-Pemu P, Lankford B, *et al.* Relation of endothelial nitric oxide synthase gene to plasma nitric oxide level, endothelial function, and blood pressure in African Americans. *Am J Hypertens* 2004;17(7):560-7.

24. Patkar S, Charita BH, Ramesh C, Padma T. High risk of essential hypertension in males with intron 4 VNTR polymorphism of eNOS gene. *Indian J Hum Genet* 2009;15(2):49-53.

25. Persu A, Vinck WJ, El Khattabi O, Janssen RG, Paulussen AD, Devuyst O, *et al.* Influence of the endothelial nitric oxide synthase gene on conventional and ambulatory blood pressure: sib-pair analysis and haplotype study. *J Hypertens* 2005;23(4):759-65.

26. Merta M, Reiterova J, Tesar V, Stekrova J, Viklicky O. Influence of the endothelial nitric oxide synthase polymorphism on the progression of autosomal dominant polycystic kidney disease and IgA nephropathy. *Ren Fail* 2002;24(5):585-93.

27. Azurmendi P, Fraga A, Muchnik C, Dos Ramos Farias M, Galan F, Guerra D, *et al.* [Progression of autosomic dominant polycystic kidney disease. Influence of endothelial NO synthase (ecNOS) and renin angiotensin system gene polymorphisms]. *Medicina (B Aires)* 2004;64(2):139-42.

28. Wang D, Iversen J, Strandgaard S. Endothelium-dependent relaxation of small resistance vessels is impaired in patients with autosomal dominant polycystic kidney disease. *J Am Soc Nephrol* 2000;11(8):1371-6.

29. Lamnissou K, Zirogiannis P, Trygonis S, Demetriou K, Pierides A, Koptides M, *et al.* Evidence for association of endothelial cell nitric oxide synthase gene polymorphism with earlier progression to end-stage renal disease in a cohort of Helens from Greece and Cyprus. *Genet Test* 2004;8(3):319-24.

30. Elshamaa MF, Sabry S, Badr A, El-Ahmady M, Elghoroury EA, Thabet EH, *et al.* Endothelial nitric oxide synthase gene intron4 VNTR polymorphism in patients with chronic kidney disease. *Blood Coagul Fibrinolysis* 2011;22(6):487-92.